All Updates

All Updates

icon
Filter
Management news
FDA approval
iRhythm receives FDA 510(k) clearance for Zio AT cardiac monitor updates
Preventive Healthcare
Nov 4, 2024
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Product updates
Microsoft launches Copilot Actions for workplace automation
Foundation Models
Yesterday
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Preventive Healthcare

Preventive Healthcare

Nov 4, 2024

iRhythm receives FDA 510(k) clearance for Zio AT cardiac monitor updates

Management news
FDA approval

  • iRhythm Technologies, a manufacturer of cardiac monitoring systems, has received its second FDA 510(k) clearance for design modifications and labeling updates to its Zio AT wearable cardiac monitoring system. This clearance comes a week after the first 510(k) clearance for design modifications.

  • To strengthen its quality management system, iRhythm has expanded its regulatory and quality staff from 20 to over 100 employees, hired a new quality management leader, and partnered with a consulting firm for internal audits. The company has also postponed its FDA submission for the next-generation Zio MCT device to Q3 2025, with launch expected in 2026.

  • Analyst QuickTake: In May 2023, the FDA issued a warning letter to iRhythm Technologies, highlighting serious compliance issues regarding its Zio AT mobile cardiac telemetry device. The recent clearance addresses design modifications and required labeling updates regarding manufacturing facility issues this warning letter highlights.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.